Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571

被引：3

作者：

Prejzner, W

Knopinska-Posluszny, W

Mikolajczuk, J

Langowska, B

Hellmann, A

机构：

[1] Med Acad Gdansk, Dept Haematol, PL-80211 Gdansk, Poland

[2] Med Acad Gdansk, Dept Clin Biochem, PL-80211 Gdansk, Poland

来源：

CLINICAL AND LABORATORY HAEMATOLOGY | 2003年 / 25卷 / 05期

关键词：

STI571; chronic myeloid leukemia; clonogenic capacity;

D O I：

10.1046/j.1365-2257.2003.00538.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

STI571 shows clinical activity in the treatment of chronic myelogenous leukemia, Philadelphia positive acute lymphoblastic leukemia and gastrointestinal stromal tumors. Resistance of normal progenitor cells to STI571 is essential when determining the optimal therapeutic window for patients with cancer without bone marrow involvement, and for patients with chronic myeloid leukemia who achieved complete cytogenetic remission. The effect of graded concentrations of STI571 on the clonogenic potential of normal fresh bone marrow hematopoetic progenitor cells from 13 normal individuals was analyzed. It was shown that lower concentrations of STI571 (0.1 and 0.5 mumol/l) may increase colony numbers, whereas higher concentrations (> 1 mumol/l) may reduce normal colony formation.

引用

页码：293 / 296

页数：4

共 50 条

[31] Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
Thiesing, JT
Ohno-Jones, S
Kolibaba, KS
Druker, BJ
BLOOD, 2000, 96 (09) : 3195 - 3199
[32] The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation
Uemura, N
Griffin, JD
BLOOD, 2000, 96 (09) : 3294 - 3295
[33] STI571: A tyrosine kinase inhibitor for the treatment of CML. (originally presented at ASH 1999. Abstract 1639)
O'Dwyer, M
Druker, BJ
Mauro, M
Talpaz, M
Resta, D
Peng, B
Buchdunger, E
Ford, J
Reese, SF
Capdeville, R
Sawyers, CL
ANNALS OF ONCOLOGY, 2000, 11 : 155 - 155
[34] Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571
Wolff, NC
Ilaria, RL
BLOOD, 2001, 98 (09) : 2808 - 2816
[35] Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
Weisberg, E
Griffin, JD
BLOOD, 2000, 95 (11) : 3498 - 3505
[36] Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells
Majsterek, Ireneusz
Arabski, Michal
Czechowska, Agnieszka
Pytel, Dariusz
Morawiec, Zbigniew
Morawiec-Bajda, Alina
Blasiak, Janusz
ZEITSCHRIFT FUR NATURFORSCHUNG SECTION C-A JOURNAL OF BIOSCIENCES, 2006, 61 (11-12): : 896 - 902
[37] The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
Marley, SB
Deininger, MWN
Davidson, RJ
Goldman, JM
Gordon, MY
EXPERIMENTAL HEMATOLOGY, 2000, 28 (05) : 551 - 557
[38] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
Kawaguchi, Y
Jinnai, I
Nagai, K
Yagasaki, F
Yakata, Y
Matsuo, T
Kuriyama, K
Tomonaga, M
LEUKEMIA, 2001, 15 (04) : 590 - 594
[39] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
Y Kawaguchi
I Jinnai
K Nagai
F Yagasaki
Y Yakata
T Matsuo
K Kuriyama
M Tomonaga
Leukemia, 2001, 15 : 590 - 594
[40] The tyrosine kinase inhibitor STI571 restores cell cycle arrest of peripheral blood progenitor cells from patients with chronic myelogenous leukemia in vivo.
Kraemer, A
Loeffler, H
Bergmann, J
Lahaye, T
Hochhaus, A
Gschaidmeier, H
Hehlmann, R
BLOOD, 2000, 96 (11) : 344A - 344A

← 1 2 3 4 5 →